PSA

Prostate-Specific Antigen

Sonstiges

Zuletzt geprüft: 7. April 2026. Quellenansatz: Standardkontext zur Laborinterpretation, allgemeine medizinische Referenzmaterialien sowie öffentliche Gesundheits- oder klinische Leitlinien, sofern relevant.

Was ist Prostate-Specific Antigen?

Prostate-specific antigen (PSA) is a serine protease glycoprotein produced almost exclusively by the epithelial cells of the prostate gland. Its physiological function is to liquefy the seminal coagulum after ejaculation, facilitating sperm motility. PSA circulates in the blood in two main forms: complexed PSA (bound to alpha-1-antichymotrypsin and other protease inhibitors, comprising 70–90% of total PSA) and free PSA (unbound, comprising 10–30% of total PSA). Total PSA measures both forms combined. Small amounts of PSA normally leak into the bloodstream, and the level reflects prostate size, integrity, and pathology.

PSA is the most widely used biomarker for prostate cancer screening and monitoring, though it is organ-specific rather than cancer-specific—any condition affecting the prostate can elevate PSA. Since its introduction in the late 1980s, PSA screening has been one of the most debated topics in medicine. While PSA screening can detect prostate cancer early, many detected cancers are indolent and would never cause harm, leading to potential overdiagnosis and overtreatment with significant side effects (incontinence, erectile dysfunction). Current guidelines from the AUA and USPSTF recommend shared decision-making for PSA screening in men aged 55–69, weighing individual risk factors and values.

Warum der Wert wichtig ist

PSA remains the cornerstone of prostate cancer detection and monitoring despite its limitations. An elevated PSA can lead to biopsy and early detection of aggressive prostate cancer, which is curable when caught early—the 5-year survival rate for localized prostate cancer exceeds 99%. PSA is also essential for monitoring men with known prostate cancer: after radical prostatectomy, any detectable PSA suggests recurrence; after radiation therapy, a rising PSA (biochemical recurrence) triggers further evaluation. PSA kinetics—including PSA velocity (rate of change over time) and PSA doubling time—provide additional prognostic information. Free PSA percentage helps distinguish cancer from benign conditions: a lower free PSA percentage (<10%) increases cancer suspicion, while a higher percentage (>25%) suggests benign disease.

Normale Referenzbereiche

GruppeBereichEinheit
Men 40–49 years0–2.5ng/mL
Men 50–59 years0–3.5ng/mL
Men 60–69 years0–4.5ng/mL
Men 70–79 years0–6.5ng/mL
General screening threshold<4.0ng/mL

Referenzbereiche können je nach Labor variieren. Vergleichen Sie Ihre Ergebnisse immer mit den Bereichen Ihres Testlabors.

Was hohe PSA-Werte bedeuten

Häufige Ursachen

  • Prostate cancer
  • Benign prostatic hyperplasia (BPH)—the most common cause of mild PSA elevation
  • Prostatitis (bacterial or non-bacterial)
  • Urinary tract infection
  • Recent ejaculation (can raise PSA for 24–48 hours)
  • Vigorous exercise, particularly cycling
  • Recent prostate biopsy or cystoscopy
  • Urinary retention
  • Increasing age and prostate size

Mögliche Symptome

  • PSA elevation itself is asymptomatic—it is detected through blood testing
  • Prostate cancer: often asymptomatic early; advanced disease may cause urinary difficulty, bone pain, weight loss
  • BPH: urinary frequency, urgency, weak stream, nocturia, incomplete emptying
  • Prostatitis: pelvic pain, painful urination, fever (if bacterial)

Was zu tun ist: An elevated PSA warrants careful evaluation. Your doctor will consider your age, race, family history, PSA trend over time, and digital rectal exam findings. Additional tests may include free PSA percentage (low free PSA increases cancer suspicion), PSA density (PSA divided by prostate volume), 4Kscore or PHI (Prostate Health Index), and prostate MRI. If cancer risk is sufficiently elevated, a prostate biopsy (ideally MRI-guided) is performed. Not all elevated PSAs require biopsy—active surveillance with repeat PSA testing is appropriate in many cases.

Was niedrige PSA-Werte bedeuten

Häufige Ursachen

  • 5-alpha reductase inhibitors (finasteride, dutasteride) reduce PSA by approximately 50%
  • Obesity (dilutional effect from larger blood volume)
  • Certain herbal supplements
  • After radical prostatectomy (PSA should be undetectable)

Mögliche Symptome

  • Low PSA does not cause symptoms
  • Low PSA is generally reassuring regarding prostate cancer risk

Was zu tun ist: If taking finasteride or dutasteride, the PSA result should be doubled for accurate interpretation. Very low PSA in a man not on these medications is reassuring. After radical prostatectomy, PSA should be undetectable (<0.1 ng/mL); any rise above this threshold suggests biochemical recurrence. No intervention is needed for naturally low PSA levels.

Wann wird ein PSA-Test empfohlen?

  • As part of shared decision-making for prostate cancer screening in men aged 55–69
  • Earlier screening (age 40–54) for high-risk men (African American, family history of prostate cancer)
  • When prostate symptoms are present (urinary difficulties, pelvic pain)
  • For monitoring after prostate cancer treatment (surgery, radiation, hormonal therapy)
  • When evaluating suspected prostatitis

Häufig gestellte Fragen

No. Most men with an elevated PSA do not have prostate cancer. The most common cause of mildly elevated PSA is benign prostatic hyperplasia (BPH), which is nearly universal in older men. Only about 25% of men who undergo biopsy for an elevated PSA are diagnosed with cancer. PSA is a sensitive but not specific test—it detects prostate abnormalities, not specifically cancer. Additional tests (free PSA, MRI, biomarker panels) help refine which elevated PSAs warrant biopsy.
This is a personal decision that should be made with your doctor through shared decision-making. Current guidelines recommend discussing screening with men aged 55–69 and starting the conversation earlier (age 40–45) for high-risk groups (African American men, those with a first-degree relative diagnosed with prostate cancer before age 65). The benefits of screening include earlier detection of aggressive cancers; the risks include false positives, anxiety, unnecessary biopsies, and potential overtreatment of indolent cancers. Your individual risk factors, values, and preferences should guide the decision.
Avoid ejaculation for 48 hours before the test, as it can transiently raise PSA. Avoid vigorous cycling or activities that put pressure on the perineum for 48 hours. If you have a urinary tract infection or prostatitis, postpone the test until treatment is complete. Inform your doctor if you take finasteride or dutasteride, as these drugs reduce PSA by approximately 50% and the result must be adjusted. The blood draw itself requires no fasting.

Verwandte Biomarker

TTestosteronCrKreatinin

Quellen- und Prüfungsansatz

Biomarker-Glossarseiten sind erklärende Bildungsinhalte und sollten immer zusammen mit den Referenzbereichen und Kommentaren Ihres Labors sowie Ihrer Ärztin oder Ihres Arztes interpretiert werden. Mehr zu unseren redaktionellen Standards und unserem Prüfprozess finden Sie in unserer Redaktionsrichtlinie und Prüfprozess für Inhalte.

Möchten Sie Ihre PSA-Werte analysieren lassen?

Laden Sie Ihre Laborwerte hoch und erhalten Sie sofort eine KI-gestützte Einordnung aller Biomarker.

Laborwerte hochladen →

Medizinischer Hinweis: Diese Informationen dienen nur Bildungszwecken und ersetzen keine professionelle medizinische Beratung, Diagnose oder Behandlung. Referenzbereiche können zwischen Laboren variieren. Besprechen Sie die Interpretation Ihrer konkreten Testergebnisse immer mit Ihrer medizinischen Fachperson.

Hinweis: SymptomGPT ist kein medizinisches Diagnosetool und ersetzt keine medizinische Beratung. Wenden Sie sich immer an qualifiziertes medizinisches Fachpersonal. Wenn Sie einen medizinischen Notfall haben, rufen Sie sofort Ihre örtliche Notrufnummer an.